A Phase 2 interventional study of gemcitabine and paclitaxel in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 32 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 21st largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2006, is one of 65 in phase 2, and was the 42nd registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 31st largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2006, is one of 41 in phase 2, and was the 29th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion
Criteria:
paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
Drug: paclitaxel · Drug: bevacizumab
paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
Drug: gemcitabine · Drug: paclitaxel · Drug: bevacizumab
1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Also known as: LY188011, Gemzar
90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Also known as: Taxol
10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Also known as: Avastin
Overall Response Rate (ORR)
Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants qualified for tumor response analysis (per-protocol population).
Time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment to measured progressive disease (PD) & post-therapy until PD or other therapy initiated (up to 35 months)
Progression-free Survival (PFS)
PFS was measured from date of randomization to first date of disease progression or death from any cause. For participants not known to have died or had disease progression as of data-inclusion cut-off date, PFS duration was censored at date of last study visit prior to data-inclusion cut-off date.
Time frame: baseline to measured progressive disease or death up to 35 months (tumor assessments were performed every 2 cycles during study therapy; every 2 months during post-therapy until disease progression or new anticancer treatment initiated)
Overall Survival
Overall survival was measured from date of randomization to date of death from any cause. For participants not known to have died as of data-inclusion cut-off date, overall survival duration was censored at date of last study visit prior to the data cut-off date.
Time frame: baseline to death from any cause (up to 35 months)
Total Functional Assessment of Cancer Therapy -Breast (FACT-B): Change From Baseline to End of Therapy
FACT-B measures the following domains of health-related quality of life (HR-QL): physical well-being (PWB), social/family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), \& additional concerns of breast cancer (BCS). Total FACT-B scores range from 0-144, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for FACT-B is 7-8 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)
Physical Well Being (PWB) Subscale: Change From Baseline to End of Therapy
The PWB subscale of FACT-B measures physical well-being. Total PWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)
Social/Family Well Being (SFWB) Subscale: Change From Baseline to End of Therapy
The SFWB subscale of FACT-B measures social/family well-being. Total SFWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)
Emotional Well Being (EWB) Subscale: Change From Baseline to End of Therapy
The EWB subscale of FACT-B measures emotional well-being. Total EWB scores range from 0 to 24, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)
Functional Well Being (FWB) Subscale: Change From Baseline to End of Therapy
The FWB subscale of FACT-B measures functional well-being. Total FWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)
Breast Cancer Subscale (BCS): Change From Baseline to End of Therapy
The BCS subscale of FACT-B measures additional concerns of breast cancer . Total BCS scores range from 0 to 36, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for BCS is 2-3 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)
Trial Outcome Index-Breast (TOI-B): Change From Baseline to End of Therapy
The TOI-B represents the total of the subscales PWB,FWB, and BCS. Total TOI-B scores range from 0 to 92, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for TOI is 5-6 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)
| Milestone | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Started | 94 | 93 |
| Completed | 44 | 36 |
| Not completed | 50 | 57 |
| Withdrew: Adverse event | 21 | 19 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 12 | 16 |
| Withdrew: Physician decision | 9 | 13 |
| Withdrew: Other | 3 | 4 |
| Withdrew: Sponsor decision | 2 | 1 |
| Withdrew: Death due to study disease | 1 | 3 |
| Withdrew: Death due to adverse event(s) | 1 | 0 |
| Withdrew: Protocol entry criterion not met | 1 | 0 |
Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants qualified for tumor response analysis (per-protocol population).
| proportion of responders | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Overall Response Rate (ORR) | 0.489 (0.385 to 0.595) | 0.587 (0.479 to 0.689) |
PFS was measured from date of randomization to first date of disease progression or death from any cause. For participants not known to have died or had disease progression as of data-inclusion cut-off date, PFS duration was censored at date of last study visit prior to data-inclusion cut-off date.
| months | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Progression-free Survival (PFS) | 8.8 (0.1 to 27.3) | 11.3 (1.5 to 33.8) |
Overall survival was measured from date of randomization to date of death from any cause. For participants not known to have died as of data-inclusion cut-off date, overall survival duration was censored at date of last study visit prior to the data cut-off date.
| months | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Overall Survival | 25.0 (0.1 to 34.6) | 24.3 (1.5 to 33.8) |
FACT-B measures the following domains of health-related quality of life (HR-QL): physical well-being (PWB), social/family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), \& additional concerns of breast cancer (BCS). Total FACT-B scores range from 0-144, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for FACT-B is 7-8 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
| units on a scale | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Total Functional Assessment of Cancer Therapy -Breast (FACT-B): Change From Baseline to End of Therapy | -1.0 ± 15.10 | -10.8 ± 16.87 |
The PWB subscale of FACT-B measures physical well-being. Total PWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
| units on a scale | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Physical Well Being (PWB) Subscale: Change From Baseline to End of Therapy | -1.9 ± 5.90 | -4.0 ± 6.00 |
The SFWB subscale of FACT-B measures social/family well-being. Total SFWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
| units on a scale | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Social/Family Well Being (SFWB) Subscale: Change From Baseline to End of Therapy | 0.0 ± 3.43 | -1.9 ± 3.61 |
The EWB subscale of FACT-B measures emotional well-being. Total EWB scores range from 0 to 24, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
| units on a scale | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Emotional Well Being (EWB) Subscale: Change From Baseline to End of Therapy | 1.8 ± 3.17 | -0.2 ± 3.88 |
The FWB subscale of FACT-B measures functional well-being. Total FWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
| units on a scale | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Functional Well Being (FWB) Subscale: Change From Baseline to End of Therapy | -0.3 ± 5.38 | -3.8 ± 4.71 |
The BCS subscale of FACT-B measures additional concerns of breast cancer . Total BCS scores range from 0 to 36, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for BCS is 2-3 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
| units on a scale | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Breast Cancer Subscale (BCS): Change From Baseline to End of Therapy | -0.1 ± 5.02 | -1.9 ± 4.03 |
The TOI-B represents the total of the subscales PWB,FWB, and BCS. Total TOI-B scores range from 0 to 92, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for TOI is 5-6 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.
| units on a scale | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Trial Outcome Index-Breast (TOI-B): Change From Baseline to End of Therapy | -2.5 ± 12.53 | -9.1 ± 12.68 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel Plus Bevacizumab (PB) | — | 27/94 (28.7%) | 93/94 (98.9%) |
| Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | — | 36/93 (38.7%) | 93/93 (100%) |
| Event | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/94 | 9/93 |
| CellulitisInfections and infestations | 1/94 | 5/93 |
| DehydrationMetabolism and nutrition disorders | 4/94 | 5/93 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/94 | 5/93 |
| NeutropeniaBlood and lymphatic system disorders | 0/94 | 4/93 |
| PyrexiaGeneral disorders | 2/94 | 4/93 |
| LeukopeniaBlood and lymphatic system disorders | 1/94 | 3/93 |
| Cardiac failure congestiveCardiac disorders | 0/94 | 3/93 |
| Abdominal painGastrointestinal disorders | 3/94 | 1/93 |
| Urinary tract infectionInfections and infestations | 3/94 | 1/93 |
| Event | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) |
|---|---|---|
| FatigueGeneral disorders | 58/94 | 74/93 |
| NeutropeniaBlood and lymphatic system disorders | 39/94 | 65/93 |
| NauseaGastrointestinal disorders | 40/94 | 58/93 |
| Peripheral sensory neuropathyNervous system disorders | 49/94 | 42/93 |
| DiarrhoeaGastrointestinal disorders | 36/94 | 47/93 |
| AlopeciaSkin and subcutaneous tissue disorders | 41/94 | 44/93 |
| EpistaxisVascular disorders | 41/94 | 40/93 |
| ConstipationGastrointestinal disorders | 29/94 | 37/93 |
| AnaemiaBlood and lymphatic system disorders | 18/94 | 35/93 |
| StomatitisGastrointestinal disorders | 29/94 | 33/93 |
| Age Continuous(years) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| Mean | 57.5 ± 10.68 | 56.8 ± 9.56 | 57.2 ± 10.12 |
| Sex: Female, Male(Participants) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| Female | 94 | 93 | 187 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| Caucasian | 80 | 77 | 157 |
| African | 5 | 11 | 16 |
| Hispanic | 7 | 4 | 11 |
| East Asian | 2 | 1 | 3 |
| Region of Enrollment(participants) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| United States | 94 | 93 | 187 |
| Basis for Pathological Diagnosis(participants) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| Histopathological | 84 | 84 | 168 |
| Cytological | 10 | 8 | 18 |
| Missing | 0 | 1 | 1 |
| Breakdown According to Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| Fully Active- 0 | 57 | 60 | 117 |
| Ambulatory, Restricted Strenuous Activity- 1 | 37 | 31 | 68 |
| Missing | 0 | 2 | 2 |
| Breakdown by Estrogen Receptor (ER) Status(participants) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| Positive | 60 | 67 | 127 |
| Negative | 33 | 25 | 58 |
| Unknown | 1 | 1 | 2 |
| Breakdown by Human Epidermal Growth Factor (HER-2 NEU) Status(participants) | Paclitaxel Plus Bevacizumab (PB) | Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) | Total |
|---|---|---|---|
| Not done | 3 | 4 | 7 |
| Positive | 4 | 2 | 6 |
| Negative | 87 | 86 | 173 |
| Missing | 0 | 1 | 1 |
13 further baseline measures are reported on the registry.
The record gives a start of May 2006, a primary completion of Apr 2009 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine